Trastuzumab BS I.V.Infusion 1vial x 60mg(NK) (Trastuzumab(Genetical Recombination))

Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Trastuzumab BS I.V.Infusion
Manufacturer	Nihon Pharmaceutical Co.Ltd.
Prescription required	Yes

Description

Trastuzumab BS I.V.Infusion 1vial x 60mg(NK) (Trastuzumab(Genetical Recombination)) is a medicine catalog record in the MediPriceHub database. Active ingredient: Trastuzumab(Genetical Recombination). Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Nihon Pharmaceutical Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Gastric Cancer Medicines (Gastric Adenocarcinoma and Gastroesophageal Cancer). Pack information: 60 / 1. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

INDICATIONS AND USAGE Cefpodoxime proxetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta- lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta- lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil tablets are generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil tablets for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae , H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (in

How to Use

Use Trastuzumab(Genetical Recombination) under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Trastuzumab(Genetical Recombination). Pack size: 60 / 1. Pack unit: box. Manufacturer: Nihon Pharmaceutical Co.Ltd.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Gastric Cancer Medicines (Gastric Adenocarcinoma and Gastroesophageal Cancer). Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

This information is for reference only. Consult a qualified healthcare professional before using any medicine.